ArticleScientific reports2025
Advancing leprosy risk prediction through identification of a whole blood host transcriptomic biomarker signature including non-coding genes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated skin-lesion transcriptomics prioritises biomarker-candidate host-response genes with pharmacological annotation in leprosy type 1 reaction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy is a debilitating disease that requires early detection for effective control, yet diagnosis still relies on clinical signs. Previous RNA-Seq analysis of coding genes from leprosy patients' household contacts (HHC) who developed leprosy (progressors) and those who did not, revealed a 4-gene RNA signature, RISK4LEP, that predicted leprosy 4-61 months before clinical onset (AUC: 0.86). To improve this signature, the present study included non-coding genes and applied novel Differential Gene Expression (DGE) analyses and machine learning approaches to the RNA-Seq dataset. This strategy identified significant DGE between progressors and HHC for 40 genes. Next, the 10 most significantly different expressed genes, as well as genes from the optimal 3-gene signatures, were validated by RT-qPCR in an independent cohort. This analysis confirmed the diagnostic potential to discriminate progressors from HHC for 12 genes. Moreover, RPS21 and SNHG5 genes were each significantly higher expressed in progressors compared to diagnosed leprosy patients, suggesting their temporary role during early (preclinical) leprosy. Furthermore, the optimal 3-gene signature consisted of two non-coding genes and one coding gene (SNHG5, SNHG8, C6orf48; sensitivity: 88%; specificity: 88%; AUC: 0.96). This study thus identified an improved prospective host transcriptional risk signature in blood based on non-coding genes predicting the development of leprosy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.